Effect of gonadotropin-releasing hormone hypogonadism on insulin action as assessed by hyperglycemic clamp studies in men

Fertility and Sterility

Volumn 81, Issue 4, 2004, Pages 1092-1098

  Chauhan, Subodhsingh ^a   Collins, Karen ^a   Kruger, Michael ^a   Diamond, Michael P ^a  

^a HUTZEL HOSPITAL   (United States)

Author keywords

GnRH; Hyperglycemic clamp; Insulin action; M I ratio; Testosterone

Indexed keywords

ANDROGEN; GONADORELIN; GONADORELIN AGONIST; INSULIN; LEUPRORELIN; TESTOSTERONE;

ADULT; ARTICLE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPOGONADISM; MALE; NORMAL HUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; GLUCOSE CLAMP TECHNIQUE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSULIN; INSULIN ANTAGONISTS; LEUPROLIDE; MALE; REFERENCE VALUES; TESTOSTERONE;

EID: 1842526912     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.08.052     Document Type: Article

References (57)

1. Holmang A., Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 146:1992;505-510.
2. Cohen J.C., Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab. 64:1987;960-963.
3. Shoupe D., Lobo R.A. The influence of androgens on insulin resistance. Fertil Steril. 41:1984;385-388.
4. Marin P., Krotkiewski M., Bjorntorp P. Androgen treatment of middle-aged, obese men effects on metabolism, muscle and adipose tissues. Eur J Med. 1:1992;329-336.
5. Rebuffe-Scrive M., Marin P., Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 15:1991;791-795.
6. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 16:1992;991-997.
7. Pugeat M., Ducluzeau P.H., Mallion-Donadieu M. Association of insulin resistance with hyperandrogenia in women. Horm Res. 54:2000;322-326.
8. Pasquali R., Fabbri R., Venturoli S., Paradisi R., Antenucci D., Melchionda N. Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol. 154:1986;139-144.
9. Ehrmann D.A., Barnes R.B., Rosenfield R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 16:1995;322-353.
10. Adashi E. Hypothalamic-pituitary dysfunction in polycystic ovarian disease. Endocrinol Metab Clin N Am. 17:1988;649-666.
11. Sozen I., Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv. 55:2000;321-328.
12. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 62:1986;904-910.
13. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 83:1998;2001-2005.
14. Barbieri R.L. Insulin stimulates androgen accumulation in incubations of minced porcine theca. Gynecol Obstet Invest. 37:1994;265-269.
15. Barbieri R.L., Makris A., Ryan K.J. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril. 40:1983;237-241.
16. Barbieri R.L., Makris A., Ryan K.J. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol. 64:(3 suppl):1984;73S-80S.
17. Bergh C., Carlsson B., Olsson J.H., Selleskog U., Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 59:1993;323-331.
18. Cara J.F., Rosenfield R.L. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 123:1988;733-739.
19. Stuart C.A., Nagamani M. Insulin infusion acutely augments ovarian androgen production in normal women. Fertil Steril. 54:1990;788-792.
20. Carmina E., Lobo R.A. Polycystic ovaries in hirsute women with normal menses. Am J Med. 111:2001;602-606.
21. Bates G.W., Whitworth N.S. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril. 38:1982;406-409.
22. Barrett-Connor E., Khaw K.T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation. 78:1988;539-545.
23. Nestler J.E., Barlascini C.O., Matt D.W., Steingold K.A., Plymate S.R., Clore J.N., Blackard W.B. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1989;1027-1032.
24. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
25. Diamond M.P., Grainger D., Diamond M.C., Sherwin R.S., Defronzo R.A. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab. 83:1998;4420-4425.
26. Prelevic G.M., Wurzburger M.I., Peric L.A. Pancreatic beta cell function in polycystic ovary syndrome its relationship to body weight, serum testosterone and serum prolactin levels. Exp Clin Endocrinol. 90:1987;76-82.
27. Chang R.J., Nakamura R.M., Judd H.L., Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 57:1983;356-359.
28. Burghen G.A., Givens J.R., Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50:1980;113-116.
29. Livingstone C., Collison M. Sex steroids and insulin resistance. Clin Sci (Lond). 102:2002;151-166.
30. Abumrad N.N., Rabin D., Diamond M.P., Lacy W.W. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism. 30:1981;936-940.
31. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique a method for quantifying insulin secretion and resistance. Am J Physiol. 237:1979;E214-223.
32. Singh A.B., Hsia S., Alaupovic P., Sinha-Hikim I., Woodhouse L., Buchanan T.A., et al. the effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 87:2002;136-143.
33. Haffner S.M., Karhapaa P., Mykkanen L., Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 43:1994;212-219.
34. Diamond M.P., Wentz A.C., Cherrington A.D. Alterations in carbohydrate metabolism as they apply to reproductive endocrinology. Fertil Steril. 50:1988;387-397.
35. Morales A.J., Laughlin G.A., Butzow T., Maheshwari H., Baumann G., Yen S.S. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome common and distinct features. J Clin Endocrinol Metab. 81:1996;2854-2864.
36. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41:1992;1257-1266.
37. Bruno B., Poccia G., Fabbrini A. Insulin resistance and secretion in polycystic ovarian disease. J Endocrinol Invest. 8:1985;443-448.
38. Jialal I., Naiker P., Reddi K., Moodley J., Joubert S.M. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 64:1987;1066-1069.
39. Schriock E.D., Buffington C.K., Hubert G.D., Kurtz B.R., Kitabchi A.E., Buster J.E., Given J.R. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 66:1988;1329-1331.
40. Dunaif A., Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest. 83:1989;23-29.
41. Dunaif A., Finegood D.T. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;942-947.
42. Myers S.R., Ivey R.E., Cherrington A.D., Diamond M.P. Effect of Norgestrel on intermediary metabolism in the conscious dog. Endocr J. 1:1993;93-99.
43. Shamma FN, Rossi G, Lee G, Diamond MC, Jones E, Diamond MP. The effect of Norplant on glucose metabolism under euglycemic hyperinsulinemic conditions. Paper presented at: American Fertility Society 49th annual meeting; October 9-13, 1993; Montreal
44. Shamma F.N., Rossi G., HajHassan L., Penzias A.S., Connoly-Diamond M., Jones E., Diamond M.P. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions. Fertil Steril. 63:1995;767-772.
45. Nagamani M., Van Dinh T., Kelver M.E. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol. 154:1986;384-389.
46. Lanzone A., Fulghesu A.M., Andreani C.L., Apa R., Fortini A., Caruso A., Mancuso A. Insulin secretion in polycystic ovarian disease effect of ovarian suppression by GnRH agonist. Hum Reprod. 5:1990;143-149.
47. Dale P.O., Tanbo T., Djoseland O., Jervell J., Abyholm T. Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol (Copenh). 126:1992;132-136.
48. Dunaif A., Green G., Futterweit W., Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 70:1990;699-704.
49. Elkind-Hirsch K.E., Valdes C.T., Malinak L.R. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil Steril. 60:1993;634-641.
50. Laboureau-Soares Barbosa S., Rodien P., Rohmer V. Polycystic ovary syndrome treatment with insulin-sensitizing agents. Article in French] Ann Endocrinol (Paris). 63:2002;31-35.
51. Balen A. Ovulation induction for polycystic ovary syndrome. Hum Fertil (Camb). 3:2000;106-111.
52. Arslanian S.A., Lewy V., Danadian K., Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 87:2002;1555-1559.
53. Conway G.S. Hyperinsulinaemia and polycystic ovary syndrome. Hum Fertil (Camb). 3:2000;93-95.
54. Diamond M.P., Thornton K., Connolly-Diamond M., Sherwin R.S., DeFronzo R.A. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest. 2:1995;708-715.
55. Nestler J.E., Singh R., Matt D.W., Clore J.N., Blackard W.G. Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. Am J Obstet Gynecol. 163:1990;1243-1246.
56. Grainger D., Thornton K., Rossi G., Connolly-Diamond M., DeFronzo R.A., Sherwin R., Diamond M.P. Influence of basal androgen levels in euandrogenic women on glucose homeostasis. Fertil Steril. 58:1992;1113-1118.
57. rd, Blackard W.G. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocrinol Metab. 64:1987;180-184.